Member Info for Laura2022

PYC is also! A.I pharma Ria

PTRO moving as no stock due to middle east direct subscription when market was expecting a normal huge placing which didn't come

They have £6mln recurring revenues and £500k bank facilty plus a director loans rolled over till 2025

(See results )

PTRO moving as no stock due to middle east direct subscription when market was expecting a normal huge placing which didn't come

The directors already own 40% of the shares ,including CEO 27%

Also

Check PTRO

Middle Eastern funds have invested

The company has now been saved from going bust

The Subscription has been arranged by Divit Advisors, an investment bank based in Dubai. The new investors participating in the Subscription comprise a number of high net worth individuals who are clients of Divit Advisors, based in the Middle East. None of the subscribers will individually hold in excess of 10 per cent. of the enlarged issued share capital.

GRC International Named Official Partner of Europrivacy

 

GRC International Group PLC (AIM: GRC, "GRC" or "the Group"), the international governance, risk management and compliance organisation whose main business is cyber defence-in-depth, is pleased to announce that it is now an official partner of the European Centre for Certification and Privacy (ECCP) and can support the implementation of Europrivacy™/® related services

Seems to be back in the news alot recently, and PYC dosing tech should surely be of benefit

This is from the PYC website

Personalised Dosing Tool Development

Data Identification

Identified public domain data on treatment of prostate cancer using docetaxel for 400+ patients from the comparator arm of a clinical tria

AI & Machine Learning

Applied AI techniques such as neural networks and other machine learning approaches to identify key factors linking dose, toxicity and efficacy

 

Web-Based Tool

Developed a web-based tool that could, if approved, form the basis of a decision support system for clinicians treating patients with prostate cancer to help reduce cost of toxicity and improve outcomes for patients

These stocks are getting mentioned more and more and PYC fits this sector

Thanks for spotting that

I think after the 16th we will ne able able make an investment decision , if certainly feels that there can't be much more bad news that isn't priced in

Ralph sorry to bother you again but did you have any thoughts on the USA market for PYC please ?

This mentions USA below

Further development of our dosing tool for use in guiding the use of granulocyte/ macrophage colony stimulating factor (GCSF) - as outlined in our update on 9 January 2023. We see significant potential in the adaptation of our current personalised dosing tool to support clinical decision making on the use of this expensive biological drug and indeed the concept has received early positive feedback when tested with a small number of US clinicians

Very useful information Kidlington and Ralph

Very many thanks

So if they cannot do this can they still get funding?

Thanks so much

Taking all the bad news and headwind into account to this seems very good value going forward (pending results) and a good income (should it be maintained)

Thanks

L

that's good news ***en

What does this mean please ?

Resolution 8, proposed as an ordinary resolution relating to the disapplication of pre-emption rights, did not achieve the required 50% of votes cast and therefore was not passed.

 

Good morning

Silly question but why is the share price going down when Imvestco are adding twice?

Buys are 0.95p and 0.955p

Why do they keep showing buys like this ?

Thanks for the explanation on volume as I did not know what you meant !

I'm in one of those

pyc is very undervalued too

Amazing

I wish I had bought more than just a small amount now

It dropped from 15p and the CEO and board own 45% so you woukd think they will want to buy as they had a 42p placing in early 2022

That bio tech one is also worth a look